GB2311523A - Tryptophan urea tachykinin receptor antagonists - Google Patents
Tryptophan urea tachykinin receptor antagonists Download PDFInfo
- Publication number
- GB2311523A GB2311523A GB9705861A GB9705861A GB2311523A GB 2311523 A GB2311523 A GB 2311523A GB 9705861 A GB9705861 A GB 9705861A GB 9705861 A GB9705861 A GB 9705861A GB 2311523 A GB2311523 A GB 2311523A
- Authority
- GB
- United Kingdom
- Prior art keywords
- methyl
- amino
- carbonyl
- indolyl
- propionamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Description
TITLE 3 OF THE INVENTION TRYPTHOPHAN UREAS AS NEUROKININ ANTAGONISTS
BACKGROUND OF THE INVENTION
The invention disclosed herein is directed to certain substituted azacycles useful as tachykinin receptor antagonists. In particular, the compounds disclosed herein are neurokinin receptor antagonists.
The tachykins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are structurally similar members of a family of neuropeptides. Each of these is an agonist of the receptor types, neurokinin-l receptor (NK-1), neuorokinin-2 receptor (NK-2) and neuorokinin-3 receptor (NK-3), which are so defined according to their relative abilities to bind tachykinins with high affinity and to be activated by the natural agonists SP, NKA and NKB respectively.
The tachykinins are distinguished by a conserved carboxylterminal sequence Phe-X-Gly-Leu-Met-NH2. More specifically, substance P is a pharmacologic ally-active neuropeptide that is produced in mammals and possesses a characteristic amino acid sequence:
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
Neurokinin A possesses the following amino acid sequence: His-Lys-Thr-Asp-S er-Phe-Val-Gly-Leu-Met-NH2.
Neurokinin B possesses the following amino acid sequence: AspMet-His-Asp-Phe-Phe-Val-Gly-Leu-Met-N (Chang et al., Nature New Biol. 232, 86 (1971); D.F. Veber et awl., U.S.
Patent No. 4,680,283).
The neurokinin receptors are widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulating a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow, Phannacol. Rev., 1983, 35, 85141). The NK1 and NK2 receptor subtypes are implicated in synaptic transmission (Laneuville et al., Life Sci., 42: 1295-1305 (1988)).
Substance P acts as a vasodilator, a depressant, stimulates salivation and produces increased capillary permeability. It is also capable of producing both analgesia and hyperalgesia in animals, depending on dose and pain responsiveness of the animal (see R.C.A.
Frederickson et al., Science, 199, 1359 (1978); P. Oehme et al., Science, 208, 305 (1980)) and plays a role in sensory transmission and pain perception (T.M. Jessell, Advan. Biochem. Psychopharmacol. 28, 189 (1981)). In particular, substance P has been shown to be involved in the transmission of pain in migraine (see B.E.B. Sandberg et al., Journal of
Medicinal Chemistry, 25, 1009 (1982)), and in arthritis (Levine et al.
Science, (1984) 226, 547-549).
In the airways, it has been indicated that NK1 receptors are associated with microvascular leakage and mucus secretion, while NK2 receptors regulate smooth muscle contraction. Also, it has been shown that both substance P and neurokinin A are effective in inducing airway constriction and edema. Based on such findings, it is believed that substance P and neurokinin A may be involved in the pathogenesis of neurogenic inflammation, including allergic diseases such as asthma.
(Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al.,
Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
In experimental studies, sensory neuropeptides, especially tachykinins such as substance P and neurokinin A, can bring about many of the pathophysiological features of asthma. Neurokinin A is a very potent constrictor of human airways in vitro, and substance P causes mucus secretion in the airways. (Barnes P.J., Lancet, pp 242-44 (1986);
Rogers D.R., Aursudkij B., Barnes P.J., Euro. J. Pharmacol, 174, 28386 (1989)).
Inhalation of bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects. (Fuller R.W., Dixon
C.M.S., Cuss F.M.C., Barnes P.J., Am Rev Respir Dis, 135, 176-80 (1987)). Since the bradykinin-induced bronchoconstriction is partly opposed by anticholinergic agents and since bradykinin is only a weak constrictor of human airways in vitro, it has been suggested that the bronchoconstrictor response is partly mediated by a neural reflex.
Bradykinin stimulates vagal afferent C fibers and causes bronchoconstriction in dogs. (Kaufman M.P., Coleridge H.M., Coleridge
J.C.G., Baker D.G., J. Appl. Physio., 48, 511-17 (1980)). In guinea-pig airways, bradykinin causes a bronchoconstrictor response by way of cholinergic and sensory-nerve-mediated mechanisms. (Ichinoe M.,
Belvisi M.G., Barnes P.J., J. Pharmacol. Exp. Ther., 253, 594-99 (1990). Bradykinin-induced bronchoconstriction in human airways may therefore be due partly to tachykinin released from sensory nerve terminals via axon reflex mechanisms. Clinical trials have shown that a dual NK-1/NK-2 antagonist (such as FK-224) protects against bradykinin induced bronchocontriction in asthmatic patients. (Ichinoe,
M. et al., Lancet, , vol. 340, pp 1248-1251 (1992)).
The tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract, such as inflammatory bowel disease, ulcerative colitis and Crohn's disease, etc.
(see Mantyh et al., Neuroscience, 25 (3), 817-37 (1988) and D. Regoli in "Trends in Cluster Headache" Ed. F. Sicuteri et al., Elsevier
Scientific Publishers, Amsterdam, 1987, pp. 85-95).
It is also hypothesized that there is a neurogenic mechanism for arthritis in which substance P may play a role (Kidd et al., "A
Neurogenic Mechanism for Symmetric Arthritis" in The Lancet, 11
November 1989 and Gronblad et al., "Neuropeptides in Synovium of
Patients with Rheumatoid Arthritis and Osteoarthritis" in J. Rheumatol.
(1988) 15(12) 1807-10). Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arhritis and osteoarthritis (O'Byrne et al., in Arthritis and Rheumatism (1990) 33, 1023-8). Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions (Hamelet et al., Can. J.
Pharmacol. Physiol. (1988) 66, 1361-7), immunoregulation (Lotz et al.,
Science (1988) 241, 1218-21, Kimball et al., J. Immunol. (1988) 141 (10) 3564-9 and A. Perianin, et al., Biochem. Biophys. Res. Commun.
161, 520 (1989)) vasodilation, bronchospasm, reflex or neuronal control of the viscera (Mantyh et al., PNAS (1988) 85, 3235-9) and, possibly by arresting or slowing 5-amyloid-mediated neurodegenerative changes (Yankner et al., Science, (1990) 250, 279-82) in senile dementia of the Alzheimer type, Alzheimer's disease and Downs Syndrome.
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis (J. Luber-Narod et al., poster presented at C.I.N.P. XVIIIth Congress, 28th June-2nd
July, 1992). Antagonists selective for the substance P and/or the neurokinin A receptor may be useful in the treatment of asthmatic disease (Frossard et al., Life Sci., 49, 1941-1953 (1991); Advenier, et al., Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
SUMMARY OF THE INVENTION
This invention is directed to compounds of formula I.
The invention is also concerned with pharmaceutical formulations with these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders.
The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine and asthma.
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to compounds of formula I.
or a pharmaceutically acceptable salt thereof, wherein
is selected from the group consisting of
R2is
(a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl or CF3; (b)-N(R3)ClAalkylphenyl, wherein the C1-4alkyl may be linear
or branched, the phenyl is optionally mono di or
trisubstituted and wherein the substitutents are
independently halo, methyl, methoxy or CF3 and
n is 1, or 2; R3 is H, methyl or ethyl.
Within this embodiment there is a genus of compounds wherein
R2 is
(a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3;
(b) -NHCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3;
(c) -N(CH3)CH2phenyl, wherein the phenyl is optionally mono di
or trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3;
(d) -N(CH3)CH(CH3)phenyl, wherein the phenyl is optionally
mono di or trisubstituted phenyl wherein the substitutents
are independently halo, methyl, methoxy or CF3; and
(f) -N(CH3)CH(CH2CH3)phenyl, wherein the phenyl is optionally
mono di or trisubstituted phenyl wherein the substitutents
are independently halo, methyl, methoxy or CF3
Within this genus there is a class of compounds wherein
is selected from the group consisting of
As appreciated by those of skill in the art, halo as used wherein are intended to include chloro, fluoro, bromo and iodo.
Exemplifying the invention are the compounds of the examples including the group consisting of
(a) N-Benzyl-N-methyl-2-(S)-((spiro- 1 H-indene-,4'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (b) N-Benzyl-2-(S)- ((1 -methanesulfonyl- spiroindoline- 3,4'-piperidino)-carbonyl-amino)- 3-(3-indolyl)
propionamide,
(c) 3,5-B istrifluoromethylbenzyl 2-(S)-((spiro- lH-indene- 1 ,4'-piperidino)-carbonyl-amino)- 3- (3-indolyl)propionate,
(d) N-Benzyl-N-methyl-2-(S)-((spiroindane- 1,4'- piperidino)-carbonyl-amino)-3-(3 -indolyl)propionamide, (e) N-Benzyl-N-methyl-2-(S )-(( 1 -methanesulfonyl spiroindoline-3 ,4'-piperidino)-carbonyl-amino)-3- (3- indolyl)propionamide, (f) N-B enzyl-N-methyl-2-(S)-(( 1 -acetylspiroindoline-3 ,4' piperidino)-carbonyl-amino)-3 - (3-indolyl)propionamide, (g) N-Benzyl-N-methyl-2-(S)-(4-phenylpiperidino) carbonyl-amino)-3 -(3-indolyl)propionamide, (h) N-Benzyl-N-methyl-2-(S)-((4-benzylpiperidino) carbonyl-amino)-3-(3-indolyl)propionaniide, (i) N-Benzyl-N-methyl-2-(S)-(((4-phenyl-4-acetylamino) piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (j) N-Benzyl-N-methyl-2- (S )-((4-benzylpiperazino)- carbonyl-amino)-3-(3-indolyl)propionamide, (k) N-Benzyl-N-methyl-2-(S)-(4- (2-oxo- 1,2,3,4- tetrahydroquinazolin- 1 -yl)piperidino)-carbonyl-amino)-3 (3-indolyl)propionamide, (1) N-Benzyl-N-methyl-2-(S)-((4-(2-methoxyphenyl) piperazino)-carbonyl-amino)-3 (3 -indolyl)propionamide, (m) N-Benzyl-N-methyl-2-(S)-((4-(2-methylphenyl) piperazino)-carbonyl-amino)-3 -(3-indolyl)propionamide, (n) N-Phenyl-2-(S)-((spiroindane- 1,4'-piperidino)carbonyl-amino)-3-(3-indolyl)propionamide, (o) N-B enzyl-2- (S)- ((spiroindane- 1 ,4'-piperidino)carbonyl-amino)-3 -(3-indolyl)propionamide, (p) N-(2-Methylbenzyl)-2-(S)-((spiroindane- 1,4'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (o) N-(3-Methylbenzyl)-2-(S)-((spiroindane- 1,4'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (p) N-(4-Methylbenzyl)-2-(S)-((spiroindane. 1,4'- piperidino)-carbonyl-amino)-3- (3-indolyl)propionamide, (q) N-(2-Phenylethyl)-2- (S)-((spiroindane- 1,4'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide , (r) N-Benzyl-N-ethyl-2- (S )-((spiroindane- 1 ,4'-piperidino)- carbonyl-amino)-3-(3-indolyl)propionamide, (s) N-( 1 (S)-Phenylethyl)-2(S)-((spiroindane- 1,4' piperidino)-carbonyl-amino)-3- (3-indolyl)propionamide, (t) N-( 1 (R)-Phenylethyl)-2(S)-((spiroindane- 1,4'piperidino)-carbonyl-amino)-3-(3 -indolyl)propionamide, (u) N- (1 (S )-Phenylpropyl)-N-methyl-2(S )-((spiroindane- 1 1,4'-piperidino)-carbonyl-amino)-3-(3-indolyl) propionamide, (v) N-( 1 (R)-Phenylpropyl)-N-methyl-2(S)-((spiroindane 1 ,4'-piperidino)-carbonyl-amino)- 3 -(3 -indolyl) propionamide, (w) N-(3-Methylphenyl)methyl-N-methyl-2-(S)-((1- methanesulfonyl- spiroindoline-3 ,4 '-piperidino)-carbonyl- amino)-3-(3-indolyl)propionamide, (x) N- (3-Trifluoromethylphenyl)methyl-N-methyl-2- (S)- ((1 -methanesulfonyl- spiroindoline-3 ,4'-piperidino)- carbonyl-amino)-3-(3 -indolyl)propionamide, (y) N-(3,5-Dichlorophenyl)methyl-N-methyl-2-(S)-(( 1 methanesulfonyl- spiroindoline-3 ,4 '-piperidino)-carbonyl- amino)-3-(3-indolyl)propionamide, (ab) N-(3,5-Dimethylphenyl)methyl-N-methyl-2-(S)-((1- methanesulfonyl-spiroindoline-3 ,4'-piperidino)-carbonyl amino)- 3-(3-indolyl)propionamide, (ac) N-((3-Chloro-5-methyl)phenyl)methyl-N-methyl-2- (S )-(( 1 -methanesulfonyl-spiroindoline-3 ,4'-piperidino)- carbonyl-amino)-3 - (3-indolyl)propionamide, (ad) N-( 1 (S)-phenyl)ethyl-N-methyl-2-(S)-(( 1 - methanesulfonyl-spiroindoline- 3 ,4'-piperidino)-carbonyl amino)- 3-(3 -indolyl)propionamide, (ae) N-B enzyl-N-methyl-2-(R)-((spiro- lH-indene- 1,4'piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide (af) N-B enzyl-N-methyl-2- (R)-(( 1 -methanesulfonyl- spiroindoline-3 ,4'-piperidino)-carbonyl-amino)-3 -(3- indolyl)propionamide,
(ag) N-Benzyl-N-methyl-2-(R)- (4-phenylpiperidino)
carbonyl-amino)-3 -(3-indolyl)propionamide,
(ah) N-Benzyl-N-methyl-2-(S)-(( 1 -methanesulfonyl- spiroindoline-3 A'-piperidino)-carbonyl-amino)A- phenylbutyramide,
(ai) N-B enzyl-N-methyl-2-(S )-(( 1 -methanesulfonyl- spiroindoline- l ,4'-piperidino)-carbonyl-amino)-3
benzyloxypropionamide,
(aj) N-Benzyl-N-methyl-2-(S)-((spiroindine- 1,4'
piperidino)-carbonyl-amino)-3-phenylpropionamide, and
(ak) N-Benzyl-N-methyl-2-(S)-((spiroindine- 1,4'
piperidino)-carbonyl-amino)-2-phenylacetamide.
In an alternative embodiment the above compounds may be co-administered with a 2-agonist such as Bambuterol, US 4,419,364 issued to Draco on 12/6/83; Bitolterol mesylate, US 4,138,581 issued to
Sterling 2/6/79; Carbuterol, US 3,763,232 issued to SmithKline 10/2/73;
Clenbuterol, US 3,536,712 issued to Boehringer Ingelheim 10/27/70;
Dopexamine, US 4,645,768 issued to Fisons 2/24/87; Formoterol, US 3,994,974 issued to Yamanouchi 11/30/76; Mabuterol, US 4,119,710 issued to Boehringer Ingelheim 10/10/78; Pirbuterol hydrochloride US 3,700,681 issued to Pfizer 10/24/72; Procaterol hydrochloride US 4,026,897 issued to Otsuka 5/31/77; Ritodrine hydrochloride US 3,410,944 issued to North American Philips 11/12/68; Brosaterol, US 4,276,299 issued to Zambon 6/30/81 and US 4,520,200 issued to
Zambon 5/28/85; Cimaterol, US 4,407,819 issued to American
Cyanamid 10/4/83; Docarpamine, US 4,228,183 issued to Tanabe 10/14/80; Salmeterol, US 4,992,474 issued to Glaxo 2/21/91 and US 5,091,422 issued to Glaxo 2125/92.
The compounds of formula I are particularly useful in the treatment of diseases or conditions that are advantageously treated by concomitant antagonism of both NK1 and NK2 receptors or NK1, NK2 and NK3 receptors. These diseases include neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
In a second alternative embodiment the compounds of formula I may be co-administered with another NK1 or NK2 antagonist such as those described in
Appln No. DO-139125, filed 08-Jun-78, Pub. 12-Dec-79; Appln No.
EP-82568, filed 22-Dec-81, Pub. 29-Jun-83; Appln No. EP-490379, filed 13-Dec-90, Pub. 17-Jun-92; Appln No. EP-353732, filed 05-Aug88, Pub. 07-Feb-90; Appln No. EP-161007, filed 13-Jan-84, Pub. 13
Nov-85; Appln No. EP-38543, filed 28-Feb-89, Pub. 05-Sep-90; Appln
No. WO8301251, filed 09-Oct-81, Pub. 14-Apr-83; Appln No. BE894602, filed 09-Oct-81, Pub. 31-Jan-83; Appln No. DE3205991, filed 19-Feb-82, Pub. 01-Sep-83; Appln No. EP-327009, filed 02-Feb-88,
Pub. 09-Aug-89; Appln No. EP-336230, filed 05-Apr-88, Pub. ll-Oct- 89; Appln No. 394989, filed 28-Apr-89, Pub. 31-Oct-90; Appln No.
AU9068010, filed 22-Dec-89, Pub. 27-Jun-91; Appln No. EP-482539, filed 24-Oct-90, Pub. 29-Apr-92; Appln No. EP-443132, filed 10-Dec90, Pub. 28-Aug-91; Appln No. EP-498069, filed 21-Dec-90, Pub. 12
Aug-92; Appln No. W09222569, filed 19-Jun-91, Pub. 23-Dec-92;
Appln No. J04297492, filed 24-Oct-91, Pub. 21-Oct-92; Appln No.
US4997853, filed 02-Dec-88, Pub. 05-Mar-91; Appln No. EP-272929, filed 24-Dec-86, Pub. 29-Jun-88; Appln No. EP-360390, filed 25-Jul88, Pub. 28-Mar-90; Appln No. US3862114, filed 22-Nov-71, Pub. 21
Jan-75; Appln No. EP-219258, filed 30-Sep-85, Pub. 22-Apr-87, Appln
No. US4742156, filed 30-Sep-85, Pub. 03-May-88; Appln No. EP401177, filed 29-May-89, Pub. 05-Dec-90; Appln No. W09202546, filed 03-Aug-90, Pub. 20-Feb-92; Appln No. EP-176436, filed 26-Sep84, Pub. 02-Apr-86; Appln No. US4680283, filed 26-Sep-84, Pub. 14 Jul-87; Appln No. WO9220661, filed 22-May-91, Pub. 26-Nov-92;
Appln No. EP-520555, filed 24-Jun-91, Pub. 30-Dec-92; Appln No. EP347802, filed 20-Jun-88, Pub. 27-Dec-89; Appln No. EP-412542, filed 10-Aug-89, Pub. 13-Feb-91; Appln No. W09005729, filed 23-Nov-88,
Pub. 31-May-90; Appln No. W09005525, filed 23-Nov-88, Pub. 31
May-90; Appln No. EP-436334, filed 04-Jan-90, Pub. 10-Jul-91; Appln
No. WO9118878, filed 31-May-90, Pub. 12-Dec-91; Appln No.
WO9118899, filed 01-Jun-90, Pub. 12-Dec-91; Appln No. WO9201688, filed 23-Jul-90, Pub. 06-Feb-92; Appln No. W09206079, filed 28-Sep90, Pub. 16-Apr-92; Appln No. WO9212152, filed 03-Jan-91, Pub. 23
Jul-92; Appln No. WO9212151, filed 10-Jan-91, Pub. 23-Ju1-92; WO9215585, filed 01-Mar-91, Pub. 29-Apr-92; Appln No. W0022676, filed 22-May-91, Pub. 26-Nov-92; Appln No. WO9221677, filed 31-May-91, Pub. 10-Dcc-92; Appln No. WO9300331, filed 20-Jun-91,
Pub. 07-Jun-93; Appln No. W09300330, filed 21-Jun-91, Pub. 07-Jan93; Appln No. WO9109844, filed 11-Jul-91, Pub. 11-Jul-91; Appln No.
EP-429366, filed 23-Nov-89, Pub. 29-May-91; Appln No. EP-430771, filed 23-Nov-89, Pub. 05-Jun-91; Appln No. EP-514274, filed 17-May 91, Pub. 19-Nov-92; Appln No. EP-514276, filed 17-May-91, Pub. 19
Nov-92; Appln No. EP-514275, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514273, filed 17-May-91, Pub. 19-Nov-92; Appln No.
EP-428434, filed 06-Nov-89, Pub. 22-May-91; Appln No. EP-474561, filed 09-May-90, Pub. 11-Mar-92; Appln No. EP-512901, filed 03 May-91, Pub. ll-Nov-92; Appln No. EP-512902, filed 03-May-91, Pub.
11-Nov-92; Appln No. EP-515240, filed 03-May-91, Pub. 25-Nov-92;
Appln No. US4472305, filed 17-May-83, Pub. 18-Sep-84; Appln No.
US4839465, filed 20-Jan-87, Pub. 13-Jun-89; Appln No. EP-101929, filed 28-Jul-82, Pub. 07-Mar-84; Appln No. WO9102745, filed 16-Aug89, Pub. 07-Mar-91; Appln No. US3912711, filed 03-Jul-72, Pub. 14
Oct-75; Appln No. US4059693, filed 11-Jun-76, Pub. 22-Nov-77; Appln
No. US4481139, filed 13-Apr-83, Pub. 06-Nov-84; Appln No.
US7358073, filed 24-Oct-88, Pub. 19-Dec-89; Appln No. US7261627, filed 24-Oct-88, Pub. 07-Mar-89, which are hereby incorporated by reference.
The compounds of formula I are useful in the prevention and treatment of a wide variety of clinical conditions (as detailed in this specification) which are characterized by overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
These conditions may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic or peripheral neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy, and neuralgia; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; disorders of bladder function; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine. Hence, these compounds are readily adapted to therapeutic use for the treatment of physiological disorders associated with the overstimulation of the tachykinin receptors, in particular NK1, NK2 and NK3.
The compounds of the present invention are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example: neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
For the treatment of any of these diseases compounds of
Formula I may be administered orally, topically, parenterally, ICV, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain swee compositions can be prepared by mixing the drug with a suitable nonirritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula I are employed.
(For purposes of this application, topical application shall include mouth washes and gargles.)
In the treatment of a condition associated with an excess of tachykinins, an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be about 0.001 to 25 mg/kg per day, about 0.005 to 10 mg/kg per day, or about 0.005 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
TACHYKININ ANTAGONISM ASSAY
The compounds of this invention are useful for antagonizing tachykinins, in particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine and asthma in a mammal in need of such treatment. This activity can be demonstrated by the following assay.
A. Receptor Expression in COS
To express the cloned human neurokinin-l receptor (NK1R) transiently in COS, the cDNA for the human NK1R was cloned into the expression vector pCDM9 which was derived from pCDM8 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site.
Transfection of 20 )lg of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 1 of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgC12, 2.4 mM K2HPO4, 0.6 mM KH2P04, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF using the IBI GENEZAPPER (IBI, New Haven, CT). The cells were incubated in 10% fetal calf serum, 2 mM glutamine, 100U/ml penicillinstreptomycin, and 90% DMEM media (GIBCO, Grand Island, NY) in 5% CO2 at 37"C for three days before the binding assay.
Similar methods were used to express the NK2 receptor.
B. Stable Expression in CHO
To establish a stable cell line expressing the cloned human
NK1R, the cDNA was subcloned into the vector pRcCMV (INVITROGEN). Transfection of 20 Rg of the plasmid DNA into CHO cells was achieved by electroporation in 800 1 of transfection buffer suplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI). The transfected cells were incubated in CHO media (10% fetal calf serum, 100 U/ml pennicilinstreptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)) in 5% C02 at 37"C until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NK1R was selected for subsequent applications such as drug screening.
Similar methods were used to express the human NK2 receptor.
C. Assay Protocol using COS or CHO
The binding assay of human NK1R expressed in either COS or CHO cells is based on the use of 125I-substance P (125I-SP, from DU
PONT, Boston, MA) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human
NK1R. Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, NJ) and resuspended in appropriate volume of the binding buffer (50 mM Tris pH 7.5, 5 mM MnC12, 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM phosphoramidon) such that 200 Cll of the cell suspension would give rise to about 10,000 cpm of specific 125I-SP binding (approximately 50,000 to 200,000 cells). In the binding assay, 500 ul of cells were added to a tube containing 20 1 of 1.5 to 0.25 nM of 125I-SP and 5 1 of unlabeled substance P or any other test compound in DMSO. The tubes were incubated at 4"C or at room temperature for 1 hour with gentle shaking. The bound radioactivity was separated from unbound radioactivity by GF/C filter (BRANDEL, Gaithersburg, MD) which was pre-wetted with 0.1% polyethylenimine. The filter was washed with 3 ml of wash buffer (50 mM Tris pH 7.5, 5 mM MnC12, 150 mM NaCl) three times and its radioactivity was determined by gamma counter. A similar assay was used for NK2 except 125I-NKA was used as the ligand.
The activation of phospholipase C by NK1R may also be measured in CHO cells expressing the human NK1R by determining the accumulation of inositol monophosphate which is a degradation product of IP3. CHO cells are seeded in 12-well plate at 250,000 cells per well.
After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of 3H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline.
LiCi is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 370C for 15 min. Substance P is added to the well at final concentration of 0.3 nM to activate the human NK1R. After 30 min of incubation at 370C, the media is removed and 0.1 N HC1 is added. Each well is sonicated at 40C and extracted with CHC13/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG 1X8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N formic acid The inositol monophosphate is eluted with 0.2 M ammonium formate-0.1 N formic acid and quantitated by beta counter.
Similar methods were used to assess antagonism at the NK2 receptor, except NKA was used as the stimulating agonist.
The compounds of of Formula I as Exemplified in the
EXAMPLES below have been found to displace radioactive ligand for the NK-1 receptor at a concentration range of 0.01 nM to 1.0 RM, for the NK-2 receptor, 0.01 nM to 5 llM, and for the NK-3 receptor, 1.0 nM to 10 RM.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. As this invention relates to tryptophan derivatives with substitution on the amine as well as the acid moieties two complementary approaches are used.
In one approach illustrated in Scheme 1 the acid group of Boctryptophan is first activated by reacting with hydroxybenzotriazole (HOBt) and a carbodiimide such as dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) in presence of a base such as N-methylmorpholine (NMM) and the intermediate is reacted with an appropriate amine or alcohol to form an amide or an ester. Other coupling protocols such as Nhydroxysuccinimide, DCC, BOP-Cl, isobutylchloroformate or carbonyldiimidazole may also be used in this step. Next the Boc protecting group is removed by treatment with an acid such as trifluoroacetic acid (TFA), formic acid or HCl-EtOAc. The free amine (or its salt) is next reacted with carbonyldiimidazole optionally in presence of a base such as triethylamine and the resulting acyl-imidazole intermediate is reacted with an azacycle to obtain the desired urea product. These required azacycles are either commercially available or are prepared by the methods described in the literature such as Parham,
W. E. et al, Journal of Organic Chemistry, 1976, 41, 2628-2633, Ong,
H. H. et al, Journal of Medicinal Chemistry, 1983, 26, 981-986, Evans,
B. E. et al, U.S. Patent 5,091,387, and Nargund, R. et al, WO 94/19367, published September 1, 1994, WO 94/13696, published June 23, 1994, 1993), EP 93/309,867,5 hereby incorporated by reference. None of the compounds in this references are claimed to be neurokinin antagonists.
Alteranatively the amine obtained after removal of the protecting group is reacted with phosgene or triphosgene to generate a carbamoyl chloride which is then reacted with the azacycle. One can also react the azacycle with carbonyl diimidazole, phosgene or triphosgene first and then the resulting acyl-imidazole or carbamoyl chloride is reacted with the tryptophan derived amine to prepare the urea.
SCHEME 1
0 0 HK H2NK OH R1 a. J4OH a. EDC, HOBt, NMM Acid NH NH bc; Amine or Alcohol a. CDI b.
@-H @e .Jk Rt NH In the second method illustrated in Scheme 2 and described in example 2, the order of derivatization is changed. In this case one starts with a tryptophan where the acid moiety is protected and the amine is first transformed to the desired urea by one of the methods discussed above. The benzyl ester protecting group is now removed by hydrogenation and the acid formed is coupled with the desired amine or an alcohol by the usual methods.
SCHEME 2
0 H0 H2N$..OPh a. CDI#JI 0 /\ Ph \ os o \ o < NH b. " 6 yNH a. H2, Pd/C b. EDC, HOBt, NMM c. Amine or Alcohol HN:.ORl 0 NH NH 62 > Although the methods described here uses a Boc protecting group for the amine moiety and a benzyl ester as a protecting group for the acid function of tryptophan, it is understood that other amine protecting groups such as Cbz, Fmoc, Alloc and acid protecting groups like t-butyl, allyl trichloroethyl ester may also be employed. The choice of the protecting group will be based on the individual compound of interest.
EXAMPLE 1 N-Benzyl-N-methvl-2-(S)-(($piro- 1 H-indene- 1 .4'-piperidino)-carbonyl amino)-3-(3-indolylOpropionamide Step A: N-Methyl-N-benzyl-2-(S)-t-butvloxycarbonvlamino- 3-(3 indolyl)propionamide.
To a suspension of 1.967 g (6.46 mmol) of t-butylcarbonyloxy-Ltryptophan in 25 mL of CH2C12 N-methylmorpholine (1 mL, 9.69 mmol) was added. To the resulting clear solution 1.05 g (7.75 mol) of hydroxybenztriazole and 1.54 g (7.76 mmol) of 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) were added. After stirring for 15 min the reaction was treated with 0.87 mL (6.79 rnmol) of N-benzyl-methylamine and the solution was stirred overnight. The reaction mixture was quenched with water and extracted with CHO12. Each CH2C12 layer was washed with 1.2 N HC1, saturated NaHC03, brine and dried. The combined filtrate was concentrated to yield 2.56 g of the title compound which was used in the next step without purification.
1H NMR (CDCl3, ppm ranges are listed because amide rotomers were present) 6 1.39 and 1.43 (2s, 9H), 2.52 and 2.73 (2s, 3H), 3.17 (d, 2H), 3.94.4 (m, 2H), 4.98 (q, 1H), 5.42 and 5.47 (2d, 1H), 6.85 -8.1 (m, 11H).
Step B: N-Methyl-N-benzyl-2-(S)-amino- 3-(3-indolyl)propionamide.
Cold trifluoroacetic acid (TFA, 4 mL) and 0.36 mL of anisole (3.28 mmol) were added to 1.215 g (2.98 mmol) of N-methyl-N-benzyl 2-(S)-t-butyloxycarbonylamino-3-(3-indolyl)propionamide and the resulting solution was stirred at 0 C for 15 min. The ice bath was removed and the solution was allowed to warm to room temperature.
After 30 min the reaction mixture was concentrated and the residue was partitioned between saturated NaHCO3 and CH2Cl2. The organic layer was washed with brine, dried and concentrated leaving 1.044 g of the title compound which was used in the next step without purification.
1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 2.72 and 2.87 (2s, 3H), 2.9-3.2 (m, 2H), 3.95-3.6 (m, 3H), 6.85-7.6 (m, 10H), 8.17 (br s, 1H).
Step C: N-Methvl-N-benzvl-2-(S)-(fspiro-lH-indene-4.1'-piperidino)- carbonvl-amino)-3-(3-indolyi)propionamide (L743.516) To a solution of 96 mg (0.325 mmol) of N-methyl-N-benzyl-2 (S)-amino-3-(3-indolyl)propionamide in 1.5 mL of THF, 58 mg (0.357 mmol) of carbonyldiimidazole (CDI) was added. After 10 min 76 mg (0.341 mmol) of spiro-1H-indene-1,4'-piperidine hydrochloride and 54 uL (0.39 rnmol) of triethylamine (Et3N) were added. A TLC of the reaction mixture after 4 h showed that the reaction was incomplete so another 30 mg (mmol) of spiro-lH-indene-1,4'-piperidine hydrochloride was added and the solution was stirred for 1 h. The reaction was quenched by addding water and extractcted with EtOAc.
The EtOAc layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by chromatography using 5060% EtOAc-Hexane to isolate 0.205 g of the title compound.
1H NMR (CDCl3, ppm ranges are listed because amide rotomers were present) 6 1.3 (m, 2H), 1.95 (m, 2H), 2.61 and 2.8 (2s, 3H), 3.0-3.3 (m, 4H), 3.9-4.6 (m, 4H), 5.28 (m, 1H), 5.49 and 5.58 (2d, 1H), 6.7-7.4 (m, 15H), 7.5 and 7.71 (2d, 1H), 8.13 and 8.23 (2br s, 1H).
EXAMPLE 2 N-B enzyl-2- (S )-( (1 -methanesulfonvl-spiroindoline-3.4'-piperidino)- carbonyl-amino)- 3-(3-indolyl)propionamide Step A: Beizyl 2-CS)- ((1 -methanesuffonyl-spiroindoline-3 A'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionate(L-744.393) To a solution of 0.331 g (1 mmol) of L-tryptophan benzyl ester in 5 mL of TIfF containing 0.31 mL (2.2 mmol) of Et3N, 0.178 g (1.1 mmol) of CDI was added. After 15 min 0.319 g (1.05 mmol) of 1 methanesulfonyl-spiroindoline-3,4'-piperidine hydrochloride and 0.16 mL (1.1 mmol) of Et3N were added and the mixture was stirred overnight. The reaction was partitioned between water and EtOAc and the layers were separated. The EtOAc layer was washed with brine, dried and concentrated. The residue was chromatographed on a flash column using 70% EtOAc-Hexane to isolate 0.58 g of the title compound.
1H NMR (CDC13) 8 1.5-1.75 (m, 4H), 2.78 (m, 2H), 2.87 (s, 3H), 3.3 (m, 2H), 3.74 (s, 2H), 3.78 (t, 2H), 4.91 (q, 1H), 5.03 (br s, 1H), 5.06 and 5.18 (ABq, 2H), 6.65 (d, 1H), 7-7.55 (m, 13H), 8.17 (br s, 1H).
Mass spectrum m/z = 587.8 (M+1).
Step B: 2-(S)-((1 -Methanesulfonvl-sDiroindoline-3 .4"-DiDeridino)- carbonyl-amino)- 3-(3 -indolyl)propionic acid
A solution of 0.46 g (0.784 mmol) of benzyl 2-(S)-((1 methanesulfonyl- spiroindoline-3 ,4'-piperidino)-carbonyl-amino)-3- (3- indolyl)propionate in 10 mL of ethanol containing 46 mg of 10% Pd/C was hydrogenated on a Parr apparatus at 40 psi. After 8 h the reaction was ca. 50% complete. The catalyst was filtered, washed with EtOAc and the combined filtrate was concentrated. The residue was dissolved in 5 mL of EtOH, diluted with 5 mL of EtOAc and 10 drops of acetic acid (HOAc) were added. Fresh 10% Pd/C (50 mg) was added and the mixture was hydrogenated on a Parr apparatus for 3 h. The catalyst was filtered through a pad of celite, the pad was rinsed with EtOAc and the combined filtrate was concentrated to yield 0.39 g of the title compound which was used in the next step without purification.
1H NMR (CDC13) 6 1.35-1.7 (m, 4H), 2.6 (t, 2H), 2.84 (s, 3H), 3.33 (br s, 2H), 3.45-3.8 (m, 4H), 4.75 (m, 1H), 5.15 (s, 1H), 6.9-7.6 (m, 9H), 8.6 (br s, 1H).
Step C: N-Benzyl-2-(S)-((1 -methanesulfonvl-spiroindoline-3.4'- piperidino)-cartonvl-amino)-3-(3-indolyl)propionamide (L-744.394) A solution of 81 mg (0.163 mmol) of 2-(S)-((1-methanesulfonyl- spiroindoline-3 ,4'-piperidino)-carbonyl-amino)-3-(3-indolyl)propionic acid in 1 mL of CH2Cl2 was treated with 27 uL (0.245 mmol) of Nmethylmorpholine, 26 mg (0.196 mmol) of hydroxybenzotriazol and 39 mg (0.196 mmol) of EDC. After 15 min 20 uL (0.179 mmol) of benzylamine was added and the solution was stirred for 2.5 h. The reaction was quenched by adding water, then extraced with CH2Cl2.
The organic layer was washed with brine, dried and concentrated. The residue was purified by prep TLC using EtOAc as eluant to isolate 80 mg of the title product.
1H NMR (CDC13) d 1.5-1.85 (m, 4H), 2.78 (q, 2H), 2.87 (s, 3H), 3.18 (dd, 1H), 3.35 (dd, 1H), 3.74 (s, 2H), 3.82 (m, 2H), 4.2-4.4 (m, 2H), 4.7 (m, 1H), 6.9-7.5 (m, 13H), 7.68 (d, 1H), 8.16 (br s, 1H).
Mass spectrum m/z = 586.8 (M+1).
EXAMPLE 3 3.5-B istrifluoromethylbenzyl 2-(S )-((spiro- 1 H-indene- 1 .4'-piperidino)- carbonvl-amino)-3-(3-indolvl)propionate The title compound was prepared the method of example 1 by substituting 3,5-bistrifluoromethylbenzyl alcohol for N-benzyl-Nmethylamine in step A.
1H NMR (CDC13) 1.3 (m, 2H), 1.93 (m, 2H), 3.1 (m, 2H), 3.84 (br d, 1H), 3.96 (br d, 1H), 4.9 (q, 1H), 5.07 (d, 1H), 5.11 (s, 2H), 6.7-7.8 (14 H), 8.18 (br s, 1H).
EXAMPLE 4 N-Benzvl-N-methyl-2-(S )-((spiroindane- 1 A'-piperidino)-carbonyl- amino)-3-(3-indolvl)propionamide Hydrogenation of N-benzyl-N-methyl-2-(S )-((spiro- 1 H-indene- 1 ,4'-piperidino).carbonyl-amino)-3 -(3-indolyl)propionamide (from example 1) in ethanol in a Parr apparatus with 10% Pd/C as a catalyst furnished the title compound.
1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1.5 (m, 2H), 1.75 (m, 2H), 2.04 (m, 2H), 2.59 and 2.79 (2s, 3H), 2.85-3.3 (m, 4H), 3.8-4.6 (m, 4H), 5.27 (m, 1H), 5.46 and 5.54 (2d, 1H), 6.9-7.4 (m, 13H), 7.49 and 7.70 (2d, 1H), 8.15 and 8.25 (2br s, 1H).
Mass spectrum m/z = 521.7 (M+1).
The following compounds (examples 5-13)were synthesized by the procedure of example 1 by substituting spiro-1H-indene-1,4'- piperidine with an appropriate amine in step C.
EXAMPLE 5 N-B enzyl-N-methyl-2- (S )-(( 1 -methanesulfonyl-spiroindoline-3 .4'- piperidino)-carbonvl-amino)-3-(3 -indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1.5-1.9 (m, 4H), 2.6-3.3 (m, 10H), 3.8-4.6 (m, 6H), 5.26 (m, 1H), 5.49 and 5.59 (2m, 1H), 6.9-7.4 (m, 15H), 7.5 and 7.71 (2d, 1H), 8.13 and 8.23 (2br s, 1H).
EXAMPLE 6 N-Benzvl-N-methvl-2-(S)-((1 -acetvlspiroindoline-3.4'-piperidino)- carbonyl-amino)- 3 -(3 -indolyl)propionamide Mass spectrum m/z = 564 (M+1).
EXAMPLE 7
N-Benzyl-N-methvl-2-(S)-(4-phenylpiperidino)-carbonyl-amino)-3-(3indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 8 1.5-1.9 (m, 5H), 2.5-3.3 (m, 7H), 4.0-4.6 (m, 4H), 5.2 (br, 1H), 5.55 (br, 1H) 6.9-7.4 (m, 14H), 7.5 and 7.7 (2d, 1H), 8.05 and 8.13 (2br s, 1H).
Mass spectrum m/z = 495 (M+1).
EXAMPLE 8 N-Benzyl-N-methyl-2- (S )-((benzylpiperidino)-carbonyl-amino)-3-(3- indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1-1.9 (m, 5H), 2.4-3.3 (m, 9H), 3.8-4.6 (m, 4H), 5.1-5.5 (m, 2H), 6.8-7.4 (m, 14H), 7.47 and 7.67 (2d, 1H), 8.05 and 8.2 (br, 1H).
Mass spectrum m/z = 509 (M+1).
EXAMPLE 9
N-Benzyl-N-methyl-2-(S)-(((4-phenyl-4-acetylamino)piperidino)- carbonyl-amino)-3-(3-indolyl)propionamide
Mass spectrum m/z = 552 (M+1).
EXAMPLE 10 N-Benzyl-N-methyl-2-( S )-( (4-benzylpiperazino)-carbonyl-amino) 3- (3- indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 2.36 (m, 4H), 2.56 and 2.76 (2s, 3H), 3.1-3.6 (m, 8H), 4.054.55 (m, 2H), 5.29 (m, 1H), 5.45 and 5.53 (2br, 1H), 6.8-7.3 (m, 14H), 7.48 and 7.66 (2d, 1H), 8.25 (br, 1H).
Mass spectrum m/z = 510.7 (M+1).
EXAMPLE 11 N-B enzyl-N-methyl-2- (S )-(4- (2-oxo- 1.2.3 .4-tetrahydroquinazolin- 1 vl)piperidino)-carbonyl-amino)-3 - (3 -indolyl)propionamide Mass spectrum m/z = 565 (M+1).
EXAMPLE 12 N-Benzvl-N-methyl-2-(S)-((4- (2-methoxyphenyl)piperazino)-carbonvl- amino)-3-(3-indolvl)propionamide Mass spectrum m/z = 526 (M+1).
EXAMPLE 13
N-Benzyl-N-methyl-2-(S)-((4-(2-methylphenyl)piperazino)-carbonyl- amino)-3-(3-indolvl)propionamide Mass spectrum m/z = 510 (M+1).
The following compounds (examples 14-30) were prepared by a procedure analogous to that described in example 2.
EXAMPLE 14 N-Phenvl-2-(S)-((spiroindane- 1.4'-piperidino)-carbonyl-amino)-3-(3- indolvl)propionamide 1H NMR (CDC13) 6 1.42 (m, 2H), 1.5-1.8 (m, 2H), 1.95 (t, 2H), 2.87 (m, 4H), 3.2-3.45 (m, 2H), 3.72 (br d, 1H), 3.87 (br d, 1H), 4.88 (q, 1H), 5.4 (br s, 1H), 6.9-7.4 (m, 13H), 7.7 (d, 1H), 8.23 (br s, 1H), 8.8 (br s, 1H).
Mass spectrum m/z = 493.6 (M+1).
EXAMPLE 15
N-Benzvl-2-(S)- ((spiroindane- 1 A'-piperidino)-carbonyl-amino)-3-(3- indolyl )propionamide 1H NMR (CDC13) 6 1.45 (m, 2H), 1.7 (m, 2H), 1.99 (t, 2H), 2.89 (m, 4H), 3.17 (dd, 1H), 3.37 (dd, 1H), 3.75 (br d, 1H), 3.86 (br d, 1H), 4.3 (m, 2H), 4.71 (q, 1H), 5.28 (d, 1H), 6.3 (br s, 1H), 6.9-7.4 (m, 13H), 7.71 (d, 1H), 8.1 (br s, 1H).
Mass spectrum m/z = 507.8 (M+1).
EXAMPLE 16 N-(2-Methylbenzvl)-2-(S )-((spiroindane- 1 A'-piperidino)-carbonvl- amino)- 3- (3 -indolvl)propionamide 1H NMR (CDC13) 6 1.4-1.8 (m, 4H), 1.98 (t, 2H), 2.12 (s, 3H), 2.89 (m, 4H), 3.17 (dd, 1H), 3.36 (dd, 1H), 3.75 (br d, 1H), 3.86 (br d, 1H), 4.28 (m, 2H), 4.71 (q, 1H), 5.31 (br, 1H), 6.25 (br s, 1H), 6.9-7.4 (m, 12H), 7.7 (d, 1H), 8.2 (br s, 1H).
Mass spectrum m/z = 521.7 (M+1).
EXAMPLE 17 N-(3-Methylbenzyl)-2-(S )-((spiroindane- 1 .4'-piperidino)-carbonvl- amino)-3-(3-indolyl )propionamide 1H NMR (CDC13) 8 1.4-1.8 (m, 4H), 1.99 (t, 2H), 2.27 (s, 3H), 2.89 (m, 4H), 3.17 (dd, 1H), 3.36 (dd, 1H), 3.76 (br d, 1H), 3.87 (br d, 1H), 4.25 (m, 2H), 4.7 (q, 1H), 5.29 (br, 1H), 6.3 (br s, 1H), 6.8-7.4 (m, 12H), 7.71 (d, 1H), 8.2 (br s, 1H).
Mass spectrum m/z = 521.8 (M+1).
EXAMPLE 18
N-(4-Methylbenzyl)-2-(S)-((spiroindane-1,4'-piperidino)-carbonyl- amino)-3-(3-indolyl)propionamide 1H NMR (CDCl3) 6 1.4-1.8 (m, 4H), 1.97 (t, 2H), 2.28 (s, 3H), 2.88 (m, 4H), 3.18 (dd, 1H), 3.35 (dd, 1H), 3.74 (br d, 1H), 3.85 (br d, 1H), 4.26 (m, 2H), 4.71 (q, 1H), 5.32 (br, 1H), 6.4 (br s, 1H), 6.8-7.4 (m, 12H), 7.7 (d, 1H), 8.3 (br s, 1H).
Mass spectrum m/z = 521.8 (M+1).
EXAMPLE 19 N-(2-Phenylethyl)-2-(S)-((spiroindane- 1 A'-piperidino-carbonyl- amino)-3 -(3-indolyl)propionamide 1H NMR (CDCl3) 8 1.43 (m, 2H), 1.7 (m, 2H), 1.99 (t, 2H), 2.56 (m, 2H), 2.89 (m, 4H), 3.14 (dd, 1H), 3.38 (m, 3H), 3.73 (br d, 1H), 3.84 (br d, 1H), 4.62 (q, 1H), 5.22 (br s, 1H), 5.92 (br s, 1H), 6.9-7.4 (m, 13H), 7.7 (d, 1H), 8.24 (br s, 1H).
Mass spectrum m/z = 521.7 (M+1).
EXAMPLE 20
N-Benzyl-N-ethyl-2-(S)-((spiroindane-1.4'-piperidino)-carbonvlamino)-3-(3-indolyl)propionamide
Mass spectrum m/z = 535.8 (M+1).
EXAMPLE 21
N-(1(S)-Phenylethyl)-2(S)-((spiroindane-1,4'-piperidino)-carbonyl- amino)-3-(3-indolyl)propionamide
Mass spectrum m/z = 521.8 (M+1).
EXAMPLE 22
N-(1(R)-Phenylethyl)-2(S)-((spiroindane-1.4'-piperidino)-carbonyl amino)- 3-(3 -indolyl)propionamide Mass spectrum m/z = 521.8 (M+1).
EXAMPLE 23
N-(1(S)-Phenylpropyl)-N-methyl-2(S)-((spiroindane-1,4'-piperidino)- carbonyl-amino)-3-(3-indolyl)propionamide Mass spectrum m/z = 535.8 (M+1).
EXAMPLE 24 N-( 1 (R)-Phenylpropyl)-N-methyl-2(S)-((spiroindane-1,4'-piperidino)- carbonyl-amino)-3-(3-indolyl)propionamide
Mass spectrum m/z = 535.8 (M+1).
EXAMPLE 25
N-(3-Methylphenyl)methyl-N-methyl-2-(S)-((1-methanesuffonvlspiroindoline-3 .4'-piperidino)-carbonyl-amino)-3-(3 indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1.5-1.9 (m, 4H), 2.1-3.3 (m, 13H), 3.7-4.6 (m, 6H), 5.22 (m, 1H), 5.5 and 5.6 (2br, 1H), 6.8-7.4 (m, 12H), 7.69 (d, 1H), 8.2 (br, 1H).
Mass spectrum m/z = 614 (M+1).
EXAMPLE 26
N-(3-Trifluoromethylphenyl)methyl-N-methyl-2-(5)-((1- methanesulfonyl-spiroindoline-3 A'-piperidino)-carbonyl-amino)-3-(3- indolyl)propionamide (L-746.895)
Mass spectrum m/z = 668.2 (M+1).
EXAMPLE 27 N-(3 5-Dichlorophenyl)methyl-N-methyl-2-(S)-(( l-methanesulfonvl spiroindoline-3.4'-piperidino)-carbonyl-amino!-3-(3- indolyl)propionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1.6-1.9 (m, 4H), 2.5-3.3 (m, 10H), 3.8-4.6 (m, 6H), 5.1-5.5 (m, 2H), 6.9-7.4 (m, 15H), 7.5 and 7.7 (2d, 1H), 8.l(br, 1H).
EXAMPLE 28 N-(3.5-Dimethvlphenvl)methyl-N-methyl-2-(S)-(( 1 -methanesulfonvl- spiroindoline-3 .4'-piperidino)-carbonyl-amino)-3-(3 indolyl)propionamide Mass spectrum m/z = 628.4 (M+1).
EXAMPLE 29 N-((3-Chloro-5-methyl)phenylEmethyl-N-methvl-2-(S)-(( l - methanesulfonvl-spiroindoline-3.4'-piperidino)-carbonvl-amino)-3-(3- indolvl propionami de Mass spectrum m/z = 648.4 (M+1).
EXAMPLE 30
N-(1(S)-phenyl)ethyl-N-methyl-2-(S)-((1-methanesulfonyl spiroindoline-3.4'-piperidino)-carbonyl-amino)-3-(3 indolvlOpropionamide Mass spectrum m/z = 616 (M+1).
The compounds of examples 31-37 were prepared by the method of example 1 strarting with the appropriate boc-amino acid.
EXAMPLE 31 N-Benzyl-N-methvl-2-(R)- ((spiro-i H-indene- 1 A'-piperidino)-carbonyi- amino)-3-(3-indolyl)propionamide
Mass spectrum m/z = 519 (M+1).
EXAMPLE 32 N-Benzvl-N-methvl-2-(R)-(( 1 -methanesulfonvl-spiroindoline-3 A'- piperidino) carbonyl-amino)-3-(3-indolvl)propionarnide Mass spectrum m/z = 600 (M+1).
EXAMPLE 33 N-Benzyl-N-methyl-2-(R)-(4-phenylpiperidino)-carbonyl-amino)-3- (3- indolyl)propionamide Mass spectrum m/z = 495 (M+l).
EXAMPLE 34 N-Benzvl-N-methvl-2-(S)-(( 1 -methanesulfonyl-spiroindoline- 3.4'piperidino)-carbonyl-amino)-4-phenylbutyramide 1H NMR (CDCl3, ppm ranges are listed because amide rotomers were present) d 1.6-2.0 (m, 4H), 2.6-3.0 (m, 10H), 3.8-4.05 (m, 4H), 4.3-5.0 (m, 3H), 5.5 and 5.57 (2br s, 1H), 7.0-7.4 (m, 14 H).
EXAMPLE 35
N-Benzyl-N-methvl-2-(S)-((1-methanesulfonyl-spiroindoline-1,4' piperidino)-carbonyl-amino)-3-benzyloxy,propionamide Mass spectrum m/z = 591 (M+l).
EXAMPLE 36 N-B enzyl-N-methyl-2-(S)-((spiroindine- 1.4'-piperidino)-carbonvl- amino)-3-phenylpropionamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 1.34 (m, 2H), 2.0 (m, 2H), 2.66 and 2.85 (2s, 3H), 2.95-3.3 (m, 4H), 3.9-4.7 (m, 4H), 5.15 (m, 1H), 5.36 and 5.47 (2d, 1H), 6.77.35 (m, 16H).
EXAMPLE 37 N-B enzvl-N-methyl-2- (S)- ((spiroindine- 1 A'-piperidino)-carbonyl- amino)-2-phenylacetamide 1H NMR (CDC13, ppm ranges are listed because amide rotomers were present) 6 1.34 (m, 2H), 2.0 (m, 2H), 2.82 and 2.87 (2s, 3H), 3.16 (m, 2H), 4.0-4.75 (m, 4H), 5.87 and 5.92 (2d, 1H), 6.23 (m, 1H), 6.7-7.5 (m, 16H).
Table 1
Example No hNK1(IC50 nM) hNK2 (IC50 nM)
1 40 10
2 70 40
3 1 > 1000
4 50 8
5 20 12
6 15 30
7 60 50
8 90 25
9 60 > 100
10 60 100
11 100 60
12 20 25
13 30 15
14 > 1000 650
15 100 35
16 100 15
17 60 65
18 100 200
19 200 56
20 120 25
Table 1 (Cont.) 21 80 16 22 1000 28 23 650 30 24 1000 50 25 8 85 26 7.5 127 27 1 180 28 3 > 300 29 2 500 30 10 70 31 600 130 32 200 180 33 750 250 34 400 60 35 300 60 36 300 200 37 575 200
Claims (11)
1. A compound of formula I
or a pharmaceutically acceptable salt thereof, wherein
is selected from the group consisting of
R2is (a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl or CF3; (b)-N(R3)Cl-4alkylphenfl, wherein the C1,Ltalkyl may be linear
or branched, the phenyl is optionally mono di or
trisubstituted and wherein the substitutents are
independently halo, methyl, methoxy or CF3 and
n is 1, or 2; R3 is H, methyl or ethyl.
2. A compound according to Claim 1 wherein
(a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3; (b)-NHCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3;
(c) -N(CH3)CH2phenyl, wherein the phenyl is optionally mono di
or trisubstituted phenyl wherein the substitutents are
independently halo, methyl, methoxy or CF3;
(d) -N(CH3)CH(CH3)phenyl, wherein the phenyl is optionally
mono di or trisubstituted phenyl wherein the substitutents
are independently halo, methyl, methoxy or CF3; and
(f) -N(CH3)CH(CH2CH3)phenyl, wherein the phenyl is optionally
mono di or trisubstituted phenyl wherein the substitutents
are independently halo, methyl, methoxy or CF3.
3. A compound according to Claim 2 wherein
is selected from the group consisting of
4. A compound according to Claim 3 wherein
R2 is
(a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3;
(b) -NHCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3;
(c) -N(CH3)CH2phenyl, wherein the phenyl is optionally mono di
or trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3; and
(d) -N(CH3)CH(CH3)phenyl, wherein the phenyl is optionally
mono di or trisubstituted phenyl wherein the substitutents
are independently chloro, methyl or CF3.
5. A compound according to Claim 4 wherein
R2 is
(a) -OCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3; (b)-NHCH2phenyl, wherein the phenyl is optionally mono di or
trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3; and
(c) -N(CH3)CH2phenyl, wherein the phenyl is optionally mono di
or trisubstituted phenyl wherein the substitutents are
independently chloro, methyl or CF3.
6. A compound according to Claim 1 selected from
(a) N-Benzyl-N-methyl-2-(S)-((spiro- 1 H-indene- 1,4'- piperidino)-carbonyl-amino)-3 -(3 -indolyl)propionamide,
(b) N-B enzyl-2-(S)-(( 1 -methanesulfonyl-spiroindoline- 3 ,4'-piperidino)-carbonyl-amino)-3-(3-indolyl) propionamide,
(c) 3 ,5-Bistrifluoromethylbenzyl 2-(S)-((spiro- 1 H-indene 1 ,4'-piperidino)-carbonyl-amino)-3-(3-indolyl)propionate, (d) N-Benzyl-N-methyl-2-(S)- ((spiroindane- 1,4'- piperidino)-carbonyl-amino)-3 - (3 -indolyl)propionamide, (e) N-B enzyl-N-methyl-2 -(S )-(( 1 -methanesulfonyl- spiroindoline-3 ,4'-piperidino)-carbonyl- amino)-3- (3 - indolyl)propionamide,
(f) N-Benzyl-N-methyl-2-(S)-(( 1 -acetylspiroindoline-3 ,4'- piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (g) N-Benzyl-N-methyl-2-(S )-(4-phenylpiperidino) carbonyl-amino)-3 -(3 -indolyl)propionamide, (h) N-Benzyl-N-methyl-2-(S)-((4-benzylpiperidino) carbonyl-amino)-3 -(3-indolyl)propionamide, (i) N-B enzyl-N-methyl-2-(S)-(((4-phenyl4-acetylamino) piperidino)-carbonyl -amino)-3-(3 -indolyl)propionamide , (j) N-Benzyl-N-methyl-2-(S)-((4-benzylpiperazino) carbonyl-amino)-3-(3-indolyl)propionamide, (k) N-Benzyl-N-methyl-2-(S)-(4-(2-oxo- 1,2,3,4tetrahydroquinazolin- l-yl)piperidino)-carbonyl-amino)-3 (3-indolyl)propionamide, (1) N-B enzyl-N-methyl-2-(S)-((4(2-methoxyphenyl) piperazino)-carbonyl-amino)-3 -(3 -indolyl)propionamide, (m) N-B enzyl-N-methyl-2-(S )-((4- (2-methylphenyl) piperazino)-carbonyl-amino)-3-(3-indolyl)propionamide, (n) N-Phenyl-2-(S)-((spiroindane- 1 ,4'-piperidino)- carbonyl-amino)-3 - (3-indolyl)propionamide, (o) N-Benzyl-2-(S)-((spiroindane- 1 ,4'-piperidino)- carbonyl-amino)-3 - (3-indolyl)propionamide, (p) N- (2-Methylbenzyl)-2-(S )-((spiroindane- 1,4' piperidino)-carbonyl-amino)-3- (3-indolyl)propionamide, (o) N-(3-Methylbenzyl)-2-(S)-((spiroindane- 1,4' piperidino)-carbonyl-amino)-3- (3 -indolyl)propionamide, (p) N- (4-Methylbenzyl)-2-(S )-((spiroindane- 1,4' piperidino)-carbonyl-amino)-3 - (3-indolyl)propionamide, (q) N-(2-Phenylethyl)-2-(S)-((spiroindane- 1,4' piperidino)-carbonyl-amino)-3 - (3 -indolyl)propionamide, (r) N-B enzyl-N-ethyl-2-(S )-((spiroindane- 1,4' -piperidino)- carbonyl-amino)-3 -(3-indolyl)propionamide, (s) N-( 1 (S)-Phenylethyl)-2(S)-((spiroindane- 1,4'piperidino)-carbonyl-amino)-3-(3-indolyl)propionamide, (t) N- (1 (R)-Phenylethyl)-2(S)-((spiroindane- 1,4'piperidino)-carbonyl-amino)-3-(3 -indolyl)propionamide, (u) N- (1 (S )-Phenylpropyl)-N-methyl-2(S )- ((spiroindane- 1 ,4'-piperidino)-carbonyl-amino)-3-(3-indolyl) propionamide, (v) N-( 1 (R)-Phenylpropyl)-N-methyl-2(S)-((spiroindane 1 ,4'-piperidino)-carbonyl-amino)-3 - (3 -indolyl) propionamide, (w) N-(3-Methylphenyl)methyl-N-methyl-2-(S)-((1- methanesulfonyl-spiroindoline-3,4'-piperidino)-carbonyl- amino)-3- (3-indolyl)propionamide, (x) N-(3-Trifluoromethylphenyl)methyl-N-methyl-2-(S) ((1 methanesulfonyl-spiroindoline-3,41-piperidino)- carbonyl-amino)-3-(3 -indolyl)propionamide, (y) N-(3,5-Dichlorophenyl)methyl-N-methyl-2-(S)-((l- methanesulfonyl-spiroindoline-3 ,4'-piperidino)-carbonyl- amino)-3-(3 -indolyl)propionamide, (ab) N-(3 ,5-Dimethylphenyl)methyl-N-methyl-2-(S)-(( 1 - methanesulfonyl-spiroindoline-3 ,4'-piperidino)-carbonylamino)-3-(3-indolyl)propionamide, (ac) N-((3-Chloro-5-methyl)phenyl)methyl-N-methyl-2 (S )-(( 1 -methanesulfonyl-spiroindoline-3 ,4'-piperidino)- carbonyl-amino)-3-(3 -indolyl)propionamide, (ad) N-( 1 (S)-phenyl)ethyl-N-methyl-2-(S )-(( 1 methanesulfonyl-spiroindoline-3 ,4'-piperidino)-carbonyl- amino)-3-(3 -indolyl)propionamide, (ae) N-Benzyl-N-methyl-2- (R)-((spiro-l H-indene-1,4'- piperidino)-carbonyl-amino)-3- (3-indolyl)propionamide (af) N-Benzyl-N-methyl-2-(R)-(( 1 -methanesulfonylspiroindoline-3 ,4'-piperidino)-carbonyl-amino)-3 -(3 indolyl)propionamide, (ag) N-Benzyl-N-methyl-2- (R)-(4-phenylpiperidino)carbonyl-amino)-3-(3-indolyl)propionamide, (ah) N-Benzyl-N-methyl-2-(S)-((1-methanesulfonyl- spiroindoline-3 ,4'-piperidino)-carbonyl-amino)4- phenylbutyramide, (ai) N-Benzyl-N-methyl-2-(S)-((1-methanesulfonyl- spiroindoline- l ,4'-piperidino)-carbonyl-amino)-3benzyloxypropionamide, (aj) N-Benzyl-N-methyl-2-(S)-((spiroindine- 1,4'piperidino)-carbonyl-amino)-3-phenylpropionamide, and (ak) N-Benzyl-N-methyl-2-(S)-((spiroindine- 1,4' piperidino)-carbonyl-amino)-2-phenylacetamide.
7. A pharmaceutical composition for antagonizing the effect of substance P in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
8. A pharmaceutical composition for the antagonizing the effect of neurokinin A, in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
9. A method for antagonizing the effect of substance P in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
10. A method for antagonizing the effect of neurokinin A in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
11. A method of treating or preventing asthma in a pateint in need thereof which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound of
Claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1400396P | 1996-03-25 | 1996-03-25 | |
| GBGB9611786.6A GB9611786D0 (en) | 1996-06-06 | 1996-06-06 | Trypthophan ureas as neurokinin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9705861D0 GB9705861D0 (en) | 1997-05-07 |
| GB2311523A true GB2311523A (en) | 1997-10-01 |
Family
ID=26309452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9705861A Withdrawn GB2311523A (en) | 1996-03-25 | 1997-03-21 | Tryptophan urea tachykinin receptor antagonists |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2311523A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| WO2000051984A1 (en) * | 1999-03-04 | 2000-09-08 | Merck Sharp & Dohme Limited | 2-aryl indole derivatives as antagonists of tachykinins |
| US6117880A (en) * | 1997-10-30 | 2000-09-12 | Merck & Co., Inc. | Somatostatin agonists |
| US6387932B1 (en) | 1999-06-25 | 2002-05-14 | Merck & Co., Inc. | Somatostatin agonists |
| US6476045B2 (en) | 2000-07-13 | 2002-11-05 | Merck Sharp & Dohme Ltd. | Azaindole derivatives and their use as therapeutic agents |
| WO2003014083A1 (en) * | 2001-08-07 | 2003-02-20 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| EP1689493A1 (en) * | 2003-12-05 | 2006-08-16 | Bristol-Myers Squibb Pharma Company | Calcitonin gene related peptide receptor antagonists |
-
1997
- 1997-03-21 GB GB9705861A patent/GB2311523A/en not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| US6117880A (en) * | 1997-10-30 | 2000-09-12 | Merck & Co., Inc. | Somatostatin agonists |
| WO2000051984A1 (en) * | 1999-03-04 | 2000-09-08 | Merck Sharp & Dohme Limited | 2-aryl indole derivatives as antagonists of tachykinins |
| US6518273B1 (en) | 1999-03-04 | 2003-02-11 | Merck Sharp & Dohme Ltd. | 2-aryl indole derivative as antagonists of tachykinins |
| US6387932B1 (en) | 1999-06-25 | 2002-05-14 | Merck & Co., Inc. | Somatostatin agonists |
| US6476045B2 (en) | 2000-07-13 | 2002-11-05 | Merck Sharp & Dohme Ltd. | Azaindole derivatives and their use as therapeutic agents |
| WO2003014083A1 (en) * | 2001-08-07 | 2003-02-20 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| US7205417B2 (en) | 2001-08-07 | 2007-04-17 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| EP1689493A1 (en) * | 2003-12-05 | 2006-08-16 | Bristol-Myers Squibb Pharma Company | Calcitonin gene related peptide receptor antagonists |
| EP1689493A4 (en) * | 2003-12-05 | 2008-04-23 | Bristol Myers Squibb Co | Calcitonin gene related peptide receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9705861D0 (en) | 1997-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5434158A (en) | Spiro-substituted azacycles as neurokinin-3 antagonists | |
| US5607936A (en) | Substituted aryl piperazines as neurokinin antagonists | |
| US5610165A (en) | N-acylpiperidine tachykinin antagonists | |
| EP0681571B1 (en) | Spiro-substituted azacycles as tachykinin receptor antagonists | |
| US5292726A (en) | N,N-diacylpiperazines | |
| US6767915B2 (en) | Substituted piperidines as melanocortin receptor agonists | |
| JP4597532B2 (en) | N- [Phenyl (piperidin-2-yl) methyl] benzamide derivatives, methods for their preparation and their use in therapy | |
| EP0708771B1 (en) | Benzyloxyquinuclidines as substance p antagonists | |
| RU2133744C1 (en) | Piperazine compounds | |
| US6013652A (en) | Spiro-substituted azacycles as neurokinin antagonists | |
| EP0593557B1 (en) | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy | |
| US7115628B2 (en) | Bridged piperidine derivatives as melanocortin receptor agonists | |
| US6916812B2 (en) | Alpha-aminoamide derivatives as melanocortin agonists | |
| US5929094A (en) | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists | |
| US8003653B2 (en) | Imidazolidinone compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease | |
| EP0593559A1 (en) | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy | |
| JPH06501267A (en) | Fused ring analogs of nitrogen-containing non-aromatic heterocycles | |
| CA2180238A1 (en) | Novel heterocyclic compounds | |
| AU2016256819C1 (en) | Aminoindane compounds and use thereof in treating pain | |
| US5869489A (en) | Trypthophan ureas as neurokinnin antagonists | |
| US20110230497A1 (en) | Biologically active amides | |
| GB2311523A (en) | Tryptophan urea tachykinin receptor antagonists | |
| EA009059B1 (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | |
| WO1998017276A1 (en) | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists | |
| US5807865A (en) | 3,3-disubstituted piperidine derivatives and their use as therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |